NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit. ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding its Huntington's disease gene therapy drug, AMT-130, during the class period from September 24, 2025, to October 31, 2025 [1] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, with AMT-130 as its leading drug candidate aimed at slowing the progression of Huntington's disease [1] - The company faced significant scrutiny due to alleged material misstatements and omissions related to its clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [1] Legal Proceedings - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1] - Investors who purchased shares during the class period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options, with a deadline to seek lead plaintiff status set for April 13, 2026 [1] Allegations - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA submission timeline [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from its Phase I/II studies were adequate for BLA submission, leading to a significant drop in share price by over 49% [1]

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

[https://securitiesclasslaw.com/securities/uniqure-loss-submission-form/?id=183769&from=4]NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QURE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 13, 2026. There is no cost or obligation to you to participate in this case.WHY GROSS LAW FIRM? The Gross Law Fi ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting information regarding its drug AMT-130 during a specific class period, leading to significant stock price decline [1]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [1]. Legal Allegations - The lawsuit claims that uniQure misrepresented the FDA approval status of its Pivotal Study for AMT-130 and downplayed the potential delay in its Biologics License Application (BLA) timeline [1]. - The complaint highlights that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission, causing uncertainty regarding the submission timeline [1]. Stock Performance Impact - Following the disclosure on November 3, 2025, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share the next trading day [1].

Core Viewpoint - uniQure N.V. is set to report its fourth quarter and full year 2025 financial results on March 2, 2026, highlighting its ongoing commitment to advancing gene therapies for severe medical conditions [1]. Group 1: Financial Reporting - The financial results will be announced before market open on March 2, 2026, followed by a conference call at 8:00 a.m. ET [1]. - The event will be accessible via webcast on uniQure's website, with a replay available for 90 days post-event [2]. Group 2: Company Overview - uniQure is recognized for its pioneering work in gene therapy, particularly for hemophilia B, marking a significant milestone in genomic medicine [3]. - The company is advancing a pipeline of proprietary gene therapies targeting conditions such as Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease, among others [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application timeline [4] - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information was revealed [4]

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [2]. - The Class Period for the lawsuit is defined as September 24, 2025, to October 31, 2025 [6]. - Investors have until April 13, 2026, to apply to serve as lead plaintiff in the class action [3][6]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials of AMT-130 and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5]. - The lawsuit claims that the statements made by uniQure lacked a reasonable basis, impacting investor decisions [5]. Group 3: Investor Actions - Investors who purchased uniQure shares during the Class Period are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal representation and recovery options [6][9]. - Investors can choose to file for lead plaintiff status or remain as absent class members without any obligation [6][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose that the design of uniQure's Pivotal Study was not fully approved by the FDA [1] - Defendants downplayed the likelihood that uniQure would have to delay its Biologics License Application (BLA) timeline to perform additional studies, despite purportedly successful results from the Pivotal Study [1] - As a result, the statements made by Defendants regarding the company's business, operations, and prospects lacked a reasonable basis [1] Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies would be adequate to support a BLA submission [1] - The company admitted that the timing of any BLA submission for AMT-130 was now unclear, revealing the falsity of prior representations that AMT-130 was on a near-term path toward accelerated approval [1] - Following this disclosure, uniQure's ordinary share price fell by $33.40 per share, or more than 49%, from a close of $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]